P R E -P R I N T Highlights:
• In Switzerland, incidence of childhood cancer increased by 18% from 1985-2014.
• Increase in incidence was mainly caused by brain tumours and leukaemias.
• Improved registration and diagnostics may have increased brain tumour incidence.
• Increasing trend for leukaemias may be real, but reasons remain elusive. Improved case ascertainment and diagnostics could account for this trend, 2,3 or the 5 trend could represent a real increase in cancer risks. [4] [5] [6] [7] [8] Most countries have seen 6 increasing trends in childhood cancers, though results vary by reporting period and 7 cancer type. 2, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Switzerland is one of the few countries with a national childhood 8 cancer registry that has been in existence for over 40 years. 21 However, registry data 9 on incidence of childhood cancer have only been published for the diagnostic period 10 1995-2005. 22,23 Trends in the incidence of childhood cancer over the whole period 11
have not yet been analysed. 12
This study is the first to assess long-term trends in incidence of childhood cancer in 13
Switzerland. The two major aims are to calculate age-standardised, age-specific, and 14 cumulative incidence for three diagnostic periods-1985-1994, 1995-2004, and 2005-15 2014-and to describe trends in age-standardised incidence over the entire period 16 from 1985 to 2014. We also assessed indices of quality of registered cases in the SCCR. 17
Methods

18
Study population and procedure 19
The Swiss Childhood Cancer Registry (SCCR) was founded by the Swiss Paediatric 20
Oncology Group (SPOG) in 1976 and initially registered patients included in clinical 21 trials. 21 Beginning in 1981, all patients treated in paediatric cancer centres were 22 systematically included. In a retrospective study covering the period 1990-2004, we 23 P R E -P R I N T discovered, however, that 16% of children with cancer had not been treated in 1 paediatric cancer centres, including infants who were diagnosed only at autopsy in 2 neonatal departments. 24 3 Between 2004 and 2007, the SCCR was reorganized according to international 4 recommendations, 25, 26 and the review of diagnoses using pathology reports, quality 5 indices, and retrospective inclusion of missed cases were introduced. Since then, the 6 SCCR improved case completeness by comparing datasets with the population-based 7 cancer registries of each Swiss canton, and by finding missed cases in mortality 8 statistics. 27 The SCCR includes >95% of all childhood cancer cases diagnosed in 9 Switzerland since 1995. 10
A clinical research coordinator in each paediatric cancer centre notifies the SCCR of 11 new cases within two months of diagnosis. Children diagnosed with cancer before they 12 reach the age of 16 years and older adolescents diagnosed with typical paediatric 13 tumours are usually treated in paediatric cancer centres in Aarau, Basel, Bellinzona, 14 Bern, Geneva, Lausanne, Lucerne, St. Gallen, and Zurich. 15 For this study, we included all children with Swiss residency at diagnosis who were 16 registered in the SCCR and diagnosed with cancer according to one of the 12 main 17 diagnostic groups of the ICCC-3 at ages 0-14 years between 1 January 1985 and 31 18 December 2014. 19
The SCCR registers patients with leukaemias and lymphomas, malignant and benign 2 CNS tumours, malignant solid tumours, and Langerhans cell histiocytosis who were 3 diagnosed at ages under 21 years in Switzerland. The registry records personal 4 information including name, sex, date of birth, address, nationality; diagnostic 5 information including exact diagnosis and its date, basis of diagnosis, site and grade of 6 primary and subsequent tumour(s), histological type and grade, immunophenotype 7 and genetics, stage at diagnosis, laterality, and site of any metastasis; and treatment 8 information that includes the name and type of treating institution, treatment type, 9 study type, and study protocol name. Diagnoses are classified according to the 10 International Classification of Diseases, tenth revision (ICD-10); topography and 11 morphology of the ICD for Oncology, third revision (ICD-O-3); and the International 12 Classification of Childhood Cancer, third edition (ICCC-3). 25, 28, 29 The study was covered 13 by the Ethics Committee of the Canton of Bern approval to the SCCR (KEK-BE: 14 166/2014). 15
Statistical methods 16
We calculated incidence rates based on population data from the Swiss Federal 17 Statistical Office. 30 To assess indices of quality, we identified cancers treated in 18 paediatric cancer centres and cancers that had microscopically verified diagnoses that 19 were confirmed from histology of a primary tumour, haematological examination of 20 peripheral blood or bone marrow, or histology of metastasis. We then calculated the 21 average number of cases diagnosed per year and the proportional distribution of ICCC-22 3 main groups during the three decades 1985-1994, 1995-2004, and 2005-2014. We 23 calculated incidence rates (IR) for ICCC-3 main groups and subgroups per decade 24 P R E -P R I N T expressed per million children, 25 with direct standardization for age using the 2010 1 European standard population. 31 We calculated cumulative IR, defined as the sum of 2 age-specific IR over each year of age from 0 to 14 years and the risk of being diagnosed 3 with cancer before the age of 15 (1 divided by the cumulative IR). We also computed 4 age-specific IRs for the age groups <1, 1-4, 5-9, and 10-14 years. The 95% confidence 5 intervals (95% CI) for the IR were calculated assuming Poisson distribution. We used R 6 version 3.2.2 for data preparation, descriptive statistics, and calculation of IRs. 7
We examined trends in annual age-standardised incidence ratios from 1985 to 2014 8 for all diagnostic groups combined, separately for boys and girls, and for main 9 diagnostic groups using JoinPoint, Version 4.0.2.2, assessing the magnitude and 10 direction of trends over time and quantifying the average annual percentage change 11 (AAPC). 11, 13, 16, 19, [32] [33] [34] [35] JoinPoint fitted straight regression lines through the data, with the 12 natural logarithm of age-standardised incidence rates as dependent variable and 13 calendar year (1985-2014) as independent variable. We used a maximum of two 14 joinpoints to detect a maximum of three different trends, with a minimum of three 15 years between joinpoints. We selected the trend lines that provided the best fit to 16 observed age-standardised incidence rates based on the ratio of the sums of squared 17 errors from the null model and the alternative model. Inference is conducted through 18
Monte Carlo permutation tests as implemented in the software. 33 19
The study population included 98 patients (2%) who were registered from death 20 certificate notifications. We had no information on ICCC-3 main group for 12 of these 21 and lacked dates of diagnosis for 75. We classified patients with missing diagnoses as 22 having had other malignant neoplasms and imputed dates of diagnosis with the 23 missforest package for R. 36 To generate the missing values we used observed data for 24
year of birth, sex, cancer diagnosis, and age at death in the imputation model. We 25
excluded the 98 cases from all analyses using the specific subgroups of ICCC-3 cancer 1 diagnoses ( Supplemental Table 1 ). 2
Results
3
In 2014 Switzerland had a population of 7.825 million inhabitants, of which 1.225 4 million were 14 years old or younger. From 1985-2014, the SCCR registered 5486 5 cancer cases in children aged 0-14 years living in Switzerland (Supplemental Figure 1) . 6
Of those, 5104 (93%) were microscopically verified ( Table 1 ). The proportion of verified 7 cases of leukaemias has remained at 100% since 1995. Microscopic verification of 8 cancer was highest in 1995-2004 and then decreased again in 2005-2014. This was due 9 to decreases in CNS tumours, retinoblastomas, and renal tumours. 10
The proportion of cancers treated in paediatric cancer centres increased from 84% 11 during 1985-1994 to 98% for 2005-2014 (Supplemental Table 2 ). The increase was 12 largest for CNS tumours and epithelial neoplasms and melanomas; the proportion of 13 CNS tumours treated in paediatric cancer centres increased from 71% in 1985-1994 to 14 98% in 2005-2014. 15 During the decade 1985-1994, 1673 cancer cases were diagnosed at age 0-14 years; 16 1880 cases were diagnosed in 1995-2004, and 1933 cases in 2005-2014 (Table 1 ). In all 17 three decades, the most common cancers were leukaemias (31-34%), CNS tumours 18 (19-23%), and lymphomas (11-12%) ( Figure 1 ). Age-standardised incidence in all three decades was highest 21 for leukaemias, CNS tumours, and lymphomas, and the overall cumulative incidence 22 before the age of 14 years rose from 2135 to 2423 per million children from 1985-1994 23 to 2005-2014. 24 P R E -P R I N T
Childhood cancer was more common in boys than in girls, with a male to female ratio 1 of 1.28 during 2005-2014 (Table 2) . The male to female ratio was largest for Burkitt's 2 lymphoma, 6.71, and smallest for thyroid carcinomas, 0.27 (Supplemental Table 1 ). 3 Table 3 lists the age-specific incidences of childhood cancer over the period 2005-2014. 4 Leukaemias and CNS tumours were among the most common cancers throughout all 5 age group, neuroblastoma until 4 years, renal tumours from 1-4 years, and lymphoma 6 from 5-14 years. 7
Overall, age-standardised childhood cancer incidence increased between 1985-2014 by 8 0.7% per year (95% CI 0.5%-1.0%), though trends differed between age groups, type of 9 cancer, and sex (Table 4, Figure 2 ). This increase was highest for children diagnosed 10 between the ages of 10 and 14 years. The annual increase of 0.8% (95% CI 0.2%-1.4%) 11 from 1985-2014 for the incidence of leukaemias was mainly driven by a 1.2% (95% CI 12 0.4%-2.0%) increase among boys (Table 4 ). The incidence of CNS tumours increased 13 annually by 3.0% (95% CI 1.3%-4.6%) from 1985-2002, but not thereafter (Table 4) . 14 Over the entire period, to 2014, the annual increase was 1.4% (95% CI 0.5%-2.4%) for 15 boys and 1.7% (95% CI 0.7%-2.7%) for girls. Incidence of epithelial neoplasms and 16 melanomas increased by 3.8% (95% CI 1.7%-6.0%) from 1985-2014, but because they 17 account for only 3% of all cancer cases (165 of 5486 total cases) this had a very small 18 effect on the overall trend (Tables 1 and 4 
). 19
Trends in Incidence of Childhood Cancer in Switzerland Sommer et al.
Overall childhood cancer incidence rates significantly increased between 1985-2014 in 2 Switzerland, mainly driven by leukaemias and CNS tumours. The trend for CNS 3 tumours plateaued in the 2000s, but continued for leukaemias and epithelial 4 neoplasms and melanomas. The increase in overall incidence rates was age-5 dependent, with no increase in preschool children up to age 4, a slight increase in 6 children 5-9 years old, and a stronger increase in young adolescents 10-14 years old. 7
International comparison 8
The proportion of microscopically verified cases in the SCCR is high (>93%), suggesting 9 excellent validity of cancer diagnoses. This is comparable to validity ranging from 92-10 98% reported in other European countries, 17, 37, 12, 1, 38, 11 and in Japan (90%), 39 the US 11 (95%), 32 and Australia (97%). 13 Lower proportions of microscopically verified cases in 12 certain tumours do not necessarily mean lower data quality, though. For 13 retinoblastoma, current treatment rarely involves surgical removal of the eye, which 14 has led to a decreasing proportion of microscopically verified cases from 41% for 1985-15 1994 to 14% during 2005-2014. Patients with low-grade gliomas and certain high-grade 16 tumours are increasingly diagnosed with imaging techniques when surgical 17 intervention puts them at high risk for functional loss; many of these patients do not 18 undergo any surgery unless it becomes inevitable. The decreasing proportion of 19 microscopically verified CNS tumours, from 92% during 1985-1994 to 82% during 2005-20 2014, reflects this. 21 Supplemental Table 3 compares the relative distribution of diagnostic groups and the 22 overall age-standardised incidence of childhood cancer in Switzerland to the Piedmont 23 region in Italy, 11 Spain, 12 Sweden, 9 France, 37 Germany, 38 Austria, 17 Western Europe 24
combined, 1 USA, 40 Canada, 41 Australia, 13 and Korea. 14 The relative distribution of 1 diagnostic groups was similar to these countries, but age-standardized leukaemia 2 incidence was among the highest, with higher values observed in only Sweden, 3
Germany, and Australia. The incidence of neuroblastoma was among the lowest, 4 excepting only Sweden and Australia. 5
Overall cancer incidence rates in Switzerland continuously rose over the whole study 6 period, from 1985-2014. Overall incidence rates increased in all world regions except 7 sub-Saharan Africa from the 1980s to 2001-2010, 1 but have remained stable in 8
Austria, 17 Ireland, 18 the USA, 19 Canada, 16 and Australia 13 in more recent time periods 9 (Supplemental Table 4 ). The increased incidence of childhood cancer observed in our 10 study is mainly attributable to leukaemia and CNS tumours. Incidence of leukaemia 11 increased steadily until 2014 without evidence of a plateau. Most countries also 12 observed an increase, 2, [7] [8] [9] [11] [12] [13] [14] 18, 20 while studies from the USA and Austria reported 13 stable leukaemia incidence ( Supplemental Table 4 ). 17, 19, 32 Leukaemia incidence in 14
Canada first increased but levelled off after 1999. 16 We observed that incidence of CNS 15 tumours increased until 2002 and plateaued thereafter, similar to Australia. 13 Many 16 studies found increases over the entire study period, 8, 11, 12, 17, 20 others found no 17 increase, 14, 16, 19, 32, 35, 42, 43 or even a decrease. 35 We also found that incidence of epithelial 18 neoplasms and melanomas increased over the entire study period, similar to the 19 USA, 10,32 Australia, 13 and Korea. 14 20
Possible reasons for increasing trend in incidence 21
The increased incidence of childhood cancer may be attributable to several factors. 22
First, improved case registration would increase the observed incidence. Patients with 23 CNS tumours, with epithelial neoplasms and melanomas, and aged 10-14 years at time 24
of cancer diagnosis increasingly have been treated in paediatric oncology centres. 1 These paediatric oncology centres collaborate closely with the SCCR and actively 2 report every newly diagnosed child. 24 Since 1985, SCCR coverage has improved from 3 85% to 95%. 27 The SCCR has retrospectively registered missed cases, but we cannot 4 exclude that some of the children with CNS tumours or children treated in earlier 5 decades in adult facilities escaped registration, and thus that earlier incidence of 6 childhood cancers is underestimated. Advances in medical diagnostics also may have 7 increased apparent incidence rates. Imaging techniques have enhanced the capacity to 8 diagnose otherwise undetected low-grade CNS tumours since the mid-1980s. 2,44 9
Finally, medical and environmental risk factors could have increased the incidence of 10 some cancers, including leukaemias in particular, which recently have increased in 11 nearly all countries. Leukaemia and CNS tumours may be associated with exposure to 12 low-level ionizing radiation, 45 which has likely increased in recent decades due to the 13 increasing use of imaging techniques that rely upon ionizing radiation, especially 14 computed tomography. 46 This might explain the age-dependent pattern of increase. 15
Other potential risk factors include genetic causes, higher birth weight and parental 16 age, increased infections, exposure to pesticides and traffic-related air pollution, as 17 well as parental exposure to benzene. [47] [48] [49] However, the results of this study do not 18 allow us to draw conclusions about specific risk factors that may have contributed to 19 the overall increasing incidence of cancer in general, and specifically of leukaemia and 20 CNS tumours. 21
Strengths and limitations of the study 22
The nationwide, population-based coverage of the SCCR with a high completeness of 23 registration is a real strength of this study. 27 Data quality was high with more than 90% 24 P R E -P R I N T of the cases having been microscopically verified. We could include recent diagnostic 1 years (until 2014) due to the fast reporting and quality control procedures in the 2 SCCR. 21 For the most recent years, the SCCR is in the process of exchanging data with 3 the cantonal cancer registries. Therefore, we may have underestimated increases in 4 incidence in the most recent period, although the SCCR missed very few cases in 5 previous linkages. The sample size was limited by the comparatively small population 6 of Switzerland, which led to wide confidence intervals for some diagnostic groups. 7
Results should thus be interpreted cautiously because trends may reflect random 8 fluctuations in incidence. 9
Conclusions 10
Changes in registration procedures and advances in medical diagnostics may explain 11 the increase observed in the incidence in CNS tumours. For leukaemia, rising incidence 12 may be real and due to changes in parental lifestyle, infections, pesticide exposure, air 13 Abbreviations: ASR, age-standardised incidence rate; CI, confidence interval; CNS, central nervous system; CR, cumulative incidence rate; ICCC-3, International Classification of Childhood Cancer, third edition.
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